Navigation Links
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
Date:5/24/2010

WALTHAM, Mass., May 24 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor for the treatment of Friedreich's ataxia.  Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.  This designation may also qualify Repligen to benefit from certain tax credits and a waiver of the company's obligation to pay the FDA application user fees for this product as required by the Prescription Drug User Fee Act. The U.S. Orphan Drug Act provides incentives for companies developing and marketing therapies for rare diseases, defined as those affecting fewer than 200,000 Americans.  There are approximately 15,000 people worldwide with Friedreich's ataxia.

"We are very pleased to receive Orphan Drug Designation for our Friedreich's ataxia program," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen.  "RG2833 is the first compound that targets activation of the defective gene responsible for Friedreich's ataxia.  If this approach is successful, it has the potential to significantly impact patients' lives."

Earlier this month, we filed an Investigational New Drug Application with the FDA for a Phase 1 study of RG2833 to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 healthy volunteers.  This study will also evaluate the phar
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Chicago, IL (PRWEB) July 31, 2014 ... wave of automation across the U.S., increasing unemployment, ... middle class. It is a Catch 22—we ... internationally, but this means fewer jobs,” says economist ... the just-released Pollina Corporate Top 10 Pro-Business States ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The Kidney Cancer ... of its monthly news magazine, Kidney Cancer News. , ... presence on a website maintained by an international news organization. ... immediate increase in viewers.” , This month’s program highlights news ... tumors analyzed in a recent study. Kidney Cancer News ...
(Date:7/30/2014)... 30, 2014 Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... highlights for the quarter ended June 30, 2014 on ... close. Regulus will host a conference ... 5:00 pm Eastern Daylight Time to discuss its second ...
(Date:7/30/2014)... 30, 2014  Decision Resources Group finds that ... in the United States ... penetration will be the level of savings achievable ... expected lower cost to patients. Payers plan to ... their pricing expectations in order to encourage physician ...
Breaking Biology Technology:ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... 7, 2011 Cellectis (Alternext: ALCLS), the ... its nuclease production capacity has increased ten-fold ... of the nuclease manufacturing gives Cellectis bioresearch, ... of Cellectis, the potential to supply the ...
... , Inc. ( www.sermo.com ), the largest online physician ... of Sermo Sponsorship, a portfolio of offerings that provides ... to engage physicians and educate them on new products ... and mobile platforms, where physicians across 68 specialties discuss ...
... Sanford Rose Associates® - San Diego, focusing exclusively on assignments ... another successful placement. Mr. John Sperzel has been selected for ... a global provider of Point of Care testing systems and ... Directors. Mr. Sperzel is a dynamic business leader ...
Cached Biology Technology:Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 2Sermo, Inc. Introduces New Sponsorship Product for Pharma, Biotech and Life Sciences 2Sermo, Inc. Introduces New Sponsorship Product for Pharma, Biotech and Life Sciences 3John Sperzel Appointed as Chief Executive Officer of ITC Nexus Dx 2
(Date:7/31/2014)... are the largest minority group in the United States, ... Latinos are obese and are 1.2 times as likely ... NYU College of Nursing student researcher Lauren Gerchow, BSN, ... that contribute to this problem by compiling a systematic ... in Latina women recently published in Nursing Research ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... in spite of waves that sometimes pound the shore ... 600 miles per hour are more prone to snap ... the American Association for the Advancement of Science meeting in ... reported that the fibrous threads she calls "nature,s bungee cords" ...
... or impacted wisdom teeth? As we humans evolved ... brains and shorter jaws, bear big babies and live longer, ... becoming the world,s most successful primate, at nearly 7 billion ... help us better deal with issues from obesity to difficult ...
... the University of Huddersfield aims to ensure that the risk of ... lead plumbing is reduced even further in line with new ... The project is being conducted in collaboration with Yorkshire ... such as European nations and the USA, have similar issues with ...
Cached Biology News:Mussels cramped by environmental factors 2Mussels cramped by environmental factors 3Is there a Neanderthal in the house? 2Research with Yorkshire Water to reduce lead in water supplies 2
Applications: (+) Immunocytochemistry and immunohistochemistry...
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Non-Protein Peroxidase Stabilizer , 1 L...
... Lysate contains the cellular components necessary for ... elongation and termination factors) but has not ... is used primarily for the isolation of ... of endogenous globin mRNA. Untreated Lysate is ...
Biology Products: